Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Patients were eligible for inclusion if the primary tumor or a metastatic lesion had increased expression of the topoisomerase 1 gene defined as a TOP1 gene copy number of ≥4 or a TOP1/CEN20 ratio of ≥2.
|
31196001 |
2019 |
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Together, these data show that TOP1 inhibitors potently suppress expression of proinflammatory cytokines, a feature that may contribute to the increased infection risk occurring in tumor patients treated with these agents.
|
31242600 |
2019 |
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
We previously reported a novel tumor associated antigen (TTA) with molecular weight around 48kDa that is a fragment derived from human DNA-topoiomerase I (TOP1).
|
29170084 |
2018 |
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Purpose Our preclinical work identified depletion of ATR as a top candidate for topoisomerase 1 (TOP1) inhibitor synthetic lethality and showed that ATR inhibition sensitizes tumors to TOP1 inhibitors.
|
29252124 |
2018 |
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Sustained tumor accumulation was observed for LMP744; γH2AX induction was demonstrated in tumors 2 and 6 hours after treatment; a decrease in TOP1 protein was observed in most lymphoma samples across all compounds and dose levels, which is consistent with the fact that tumor response was also observed at low doses LMP744.
|
30061364 |
2018 |
Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
High expression of MRP1 (89%, 8/9 tumors), TUBB3 (86%, 18/21 tumors), PTEN (85%, 28/33 tumors), TOP2A (84%, 26/31 tumors), thymidylate synthase (TS; 80%, 24/30 tumors), RRM1 (71%, 15/21 tumors), and TOP1 (63%, 19/30 tumors) were found in medulloblastoma.
|
29869738 |
2018 |
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
FL118 can show high antitumor efficacy in Top1-negative tumors, while Top1 highly positive tumors can exhibit FL118 resistance.
|
28337384 |
2017 |
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
TOP1 and centromere 20 (CEN-20) numbers were investigated by fluorescence in situ hybridization analyses in tumor tissue from 226 patients.
|
25615400 |
2015 |
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Future studies should test this concept and explore potential differences between pMMR and dMMR tumors in response to Top1 and Top2 inhibitors.
|
25777966 |
2015 |
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Despite limitations of the study the positive associations between TOP1 and objective response suggest that further analysis in larger tumor material, preferably in a randomized setting, is highly warranted.
|
24256029 |
2014 |
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
35.7% of the tumors had an increased TOP1 copy number above 4n gene copies per cell and 28.6% and 9.7% had a TOP1/CEN-20 ratio ≥1.5 or ≥2.0, respectively.
|
23110915 |
2013 |
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Poisoning of DNA topoisomerase I is the mechanism by which camptothecins interfere with tumor growth.
|
23432590 |
2013 |
Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Preclinical data indicate that resistance to CPT-based drugs might be caused by factors such as (a) poor drug accumulation in the tumor, (b) high rate of drug efflux, (c) mutations in TOP1 leading to failure in CPT docking, or (d) altered signaling triggered by the drug-TOP1-DNA complex, (e) expression of DNA repair proteins, and (f) failure to activate cell death pathways.
|
23006513 |
2013 |
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
In conclusion, the ATZD inhibited the DNA topoisomerase I activity and induced tumour cell death through apoptotic pathways.
|
23347980 |
2013 |
Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Using CEN-2 as a measurement for tumor ploidy levels, we were able to discriminate between different mechanisms of gene gain, which appeared to differ in prognostic impact.TOP1 FISH guidelines have been updated.
|
23577133 |
2013 |
Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
A TOP1 gene probe with a chromosome 20 centromere (CEN-20) reference probe was applied on normal mucosa and on tumor tissue from 50 stage III CRC patients.
|
22171973 |
2012 |
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
These results show that TOP1 amplification is associated with advanced tumours and poor prognosis in melanoma.
|
20465595 |
2010 |
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
The mechanisms and molecular determinants of tumour response to TOP1 inhibitors are reviewed, and rational combinations of TOP1 inhibitors with other drugs are considered based on current knowledge of repair and checkpoint pathways that are associated with TOP1-mediated DNA damage.
|
16990856 |
2006 |
Neoplasms
|
0.400 |
Biomarker
|
group |
CTD_human |
New advances in lung cancer chemotherapy: topotecan and the role of topoisomerase I inhibitors.
|
11598410 |
2001 |